SavedAdd your journal

Journals / Medical Network Klinik Bilimler ve Doktor / 2004 / Cilt: 10 - Sayı: 5

Efficacy of meropenem versus combination of Ceftazidime-amikacin treatment in neutropenic fever patients

Nötropenik ateşli hastalarımızda meropenem ile Seftazidim-amikasin kombinasyonunun etkinliklerinin karşılaştırılması

Fadime YÜKSEL
Hayri B. TOKSOY
Derya BÜYÜKKAYHAN
Nurullah ÇELİK
Pages
552–555
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It was concluded that in the treatment of neutropenic fever, the patients who were given meropenem monotherapy should be observed for ceftazidime plus amicasin combination therapy requirement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Infection remains the major cause of morbidity and mortality in immunocompromised children with malignancy.
📊
Key Findings & Data:Material and Methods: In our center between March 1999 and April 2003, 20 patients with hematological malignancies had 55 febrile neutropenic episodes.
💡
Conclusion & Impact:Conclusion: It was concluded that in the treatment of neutropenic fever, the patients who were given meropenem monotherapy should be observed for ceftazidime plus amicasin combination therapy requirement.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Tienamisinler · Amikasin · Seftazidim

Abstract

Objective: Infection remains the major cause of morbidity and mortality in immunocompromised children with malignancy. Empiric treatment of neutropenic fever in children should begin-immediately. This trial assessed the efficacy of meropenem versus ceftazidime-amikacin as empirical therapy for febrile neutropenia in pediatric cancer patients. Material and Methods: In our center between March 1999 and April 2003, 20 patients with hematological malignancies had 55 febrile neutropenic episodes. The first group (n: 28) received meropenem, while the second group (n: 27) was treated with ceftazidime plus amikacin. Result: The success rate with meropenem was 39% whereas with ceftazidime plus amikacin it was 66 percent. Recovery duration of fever and neutropenia was similar in both groups. Conclusion: It was concluded that in the treatment of neutropenic fever, the patients who were given meropenem monotherapy should be observed for ceftazidime plus amicasin combination therapy requirement.

Özet

Amaç: Enfeksiyonlar, kanserli immünsuprese çocuklarda mortalite ve morbiditenin en büyük nedenidir. Nötropenik ateşli hastalarda ampirik antibiyotik tedavisi hemen başlanmalıdır. Bu çalışmada febril nötropenik kanserli çocuklarda ampirik meropenem ile seftazidim-amikasin kombinasyonunun etkinlikleri değerlendirildi. Gereç ve Yöntem: Çalışmaya Mart 1999-Nisan 2003 tarihleri arasında kliniğimizde takip edilen 20 hasta ve bu hastalarda gelişen 55 nötropenik ateş atağı alındı. 28 epizota meropenem, 27 epizota seftazidim-amikasin verildi. Bulgular: Sonuçta monoterapi olarak meropenem verilen grupta iyileşme oranı %39 iken, seftazidim-amikasin verilen grupta iyileşme oranı %66 olarak tespit edildi. Her iki grup arasında ateşin düşme süresi ve nötropeniden çıkış süreleri arasında benzer etkinlik gözlendi. Sonuç: Bu sonuçlara göre meropenem monoterapisi alan hastaların, kombine antibiyotik tedavi açısından takip edilmesi gerekmektedir.

🔖

Cite This Article

YÜKSEL, F., TOKSOY, H. B., BÜYÜKKAYHAN, D., ÇELİK, N. (2004). Efficacy of meropenem versus combination of Ceftazidime-amikacin treatment in neutropenic fever patients. Medical Network Klinik Bilimler ve Doktor, Cilt: 10 - Sayı: 5, 552–555. https://ajindex.com/articles/278457

References (12)

  1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines r the Use of Antimicrobial Agents in Neutropenic Patients with ancerCID 2002
  2. Kinnunen U, Syrjala H, Koskela M, et al. Continious-lonitoring blood culture screening system improves the Section of bacteremia in neutropenic patients. Scand J Infect is 1996
  3. Pizzo PA. Management of fever in patients with cancer and eatment-induced neutropenia. N Engl J Med. 1993
  4. Cometta A, Calandra T, Gaya H, et al. Monothrapy with leropenem versus ceftazidime plus amikacin as empiric therapy »r fever granulocytopenic patients with cancer. The international ntimicrobial Therapy Cooperative Group of the European Organization for Research and treatment of Cancer and the iruppo Italiano Malattie Ematologiche Maligne dell' Adulto Infection Program. Antimicreb Agents Chemother 1996
  5. Berhman RE, Kliegman RM, Jenspn HB. Nelson Textbook of Iscliatrics. 16th ed. Philadelphia: wb Saunders, 2001
  6. Akova M, Akalın HE, Çataloğlu N, et al. Ateşli nötropenik hastalarda infekslyonların dağılımı.218 ateşli atağın incelenmesi. Hacettepe Tıp Dergisi 1989
  7. Topçu AW, Söyletir G, Doğanay M, et al. İnfeksiyon hastalıkları. 1996
  8. Wade JC. Epidemiology and prevention of infection in the compromised host. In: Robin RH, Young LS (eds). Clinical Approach to infection in the compromised host.3rd ed. New York. Plenum Medical Book Company, 1994:5. 9.European Organization for Research and Treatment of Cancer, International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada -Clinical Trial Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients J Infect Dis 1991
  9. Hughes WT, Amstrong D, Boley GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: a statement by the Infectious Disease Society of America J Infect Dis. 1990
  10. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime+amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001
  11. Feld R, De Pauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000
  12. Lindblad R, Rodjer S, Adriansson M, et al. Empiric mono- therapy for